

**MiraBiologics Enters into Drug Discovery Collaboration Agreement  
with Ono Pharmaceuticals  
To Discover and Create Biopharmaceuticals**

MiraBiologics, Inc. (Tokyo, Japan; President, Representative Director, Masuhiro Kato; “MiraBiologics”) has entered into a drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, Gyo Sagara; “Ono”) to create next-generation biopharmaceuticals using our proprietary LassoGraft Technology<sup>®</sup> that integrates cyclic peptide discovery method (RaPID System) with protein engineering.

Under the agreement, MiraBiologics will discover and create biopharmaceuticals that regulate multiple therapeutic targets selected by Ono, by using its LassoGraft Technology<sup>®</sup>. Ono obtains exclusive rights to develop and commercialize biopharmaceutical drug candidates worldwide generated by MiraBiologics through the collaboration. Ono will pay to MiraBiologics the fees based on research and development progress on a milestone basis, as well as royalties based on sales of the products after launch.

MiraBiologics Representative Director and President, Masuhiro Kato, said, “We are very pleased to enter into this drug discovery collaboration agreement with Ono Pharmaceutical Co. Ltd. Ono’s high evaluation of LassoGraft Technology<sup>®</sup>, our core technology, led to the conclusion of this agreement.” “We hope to deliver new medicines of hope to the patients and their family members through putting Ono’s achievement of creating innovative new drugs and power of MiraBiologics’ bio-pharmaceutical discovery capability together,” he added.

**About LassoGraft Technology<sup>®</sup>**

LassoGraft Technology<sup>®</sup> is a core technology of MiraBiologics, Inc. that creates target-binding proteins by inserting a pharmacophore sequence derived from a target-specific high-affinity cyclic peptide obtained by the RaPID (Random Non-standard Peptides Integrated Discovery) system into any protein, such as the Fc portion of an antibody. The application of this technology is expected to enable the rapid creation of bi- and multi-specific molecules that will be useful as next-generation multifunctional biopharmaceuticals.



**About MiraBiologics Inc.**

MiraBiologics Inc., founded in July 2017, is a bio-venture company engaged in biopharmaceutical drug discovery research. We are creating next-generation multifunctional biopharmaceuticals, such as bi-specific antibodies, reliably, quickly, and efficiently using LassoGraft Technology<sup>®</sup>, invented by Professor Hiroaki Suga of the Graduate School, the University of Tokyo, and Professor Junichi Takagi of the Institute for Protein Research, Osaka University. (<https://www.mirabiologics.com/english/>)

Contact  
contact@mirabiologics.com  
TEL : +81-3-6804-7068  
FAX : +81-3-6805-7069